Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
  • Journal club
  • Alerts
  • Subscriptions

A male with recurrent infections and mediastinal mass

Faisal Abdul Hamid, Ahmad Hadyan Husainy Hasbullah, Andrea Yu-Lin Ban
Breathe 2020 16: 200065; DOI: 10.1183/20734735.0065-2020
Faisal Abdul Hamid
Respiratory Unit, Dept of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Faisal Abdul Hamid
Ahmad Hadyan Husainy Hasbullah
Respiratory Unit, Dept of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Yu-Lin Ban
Respiratory Unit, Dept of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrea Yu-Lin Ban
  • For correspondence: andreaban@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Can you diagnose this patient with recurrent pneumonia and myasthenia gravis? https://bit.ly/2IBaxC1

A 63-year-old-male ex-smoker presented with a 2-week history of productive cough and shortness of breath. He had a history of coronary artery bypass grafting (CABG) surgery 20 years ago. He was diagnosed with ocular and bulbar myasthenia gravis 12 years ago with a positive anti-acetylcholine receptor antibody. He had no history of dyspnoea at rest, orthopnoea, paroxysmal nocturnal dyspnoea, cough, wheezing, or chest pain. He had three previous admissions for lower respiratory tract infections in the past 6 months. At two of the admissions, blood culture yielded Campylobacter jejuni and Streptococcus pneumoniae, respectively, which were treated accordingly. Sputum culture was negative. On clinical examination, he was conscious and orientated, temperature was 37.8°C, tachypnoeic (respiratory rate 25 breathes·min−1), tachycardic (heart rate 101 beats·min−1), blood pressure 120/70 mmHg and oxygen saturation 93% on room air. He had a normal jugular venous pressure and no pitting oedema around the ankles. Chest examination revealed reduced breath sounds and diffuse coarse crepitations in the middle and lower zones of the right lung. Blood tests showed: haemoglobin 12.4 g·dL−1, white cell count 21.9 x109 L−1 and platelets 660×109 L−1. A chest radiograph was performed (figure 1).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Chest radiograph.

Task 1

What is your provisional clinical diagnosis?

Answer 1

Community acquired pneumonia (CAP).

This patient was started on amoxycillin/clavulanate and azithromycin. This empiric antibiotic combination was chosen as he had non-severe CAP without risk factors for Pseudomonas aeruginosa. This is following the American Thoracic Society/Infectious Disease Society of America clinical guidelines on CAP [1]. He was also initiated on oxygen therapy to keep his saturation >94%. The British Thoracic Guidelines for CAP recommend initial oxygen saturation to be kept between 94 to 98% when a patient with pneumonia is hypoxic [2]. In this patient blood and sputum culture was negative.

Task 2

Can you describe the chest radiograph taken on admission (figure 1)?

Answer 2

The chest radiograph shows air space opacities in the right middle zone. There is presence of sternal wires in keeping with past history of CABG. There is also an incidental finding of a widened mediastinum.

The mediastinum is said to be widened when the width is >6–8 cm. The mediastinum is a anatomic space which contains vital structures. It can be divided into the pre-vascular (anterior), visceral (middle) and paravertebral (posterior). The pre-vascular component contains the thymus, fat, lymph nodes and left brachiocephalic vein. The visceral components are trachea, carini, oesophagus, lymph nodes, heart, aorta, superior vena cava, intrapericardial pulmonary arteries and thoracic duct. The paravertebral component is paravertebral soft tissues [3].

The patient may likely have a pre-vascular (anterior) tumour. In view of the history of myasthenia gravis we entertained the diagnosis of a thymoma. He improved after 5 days of amoxicillin/clavulanate and azithromycin.

Task 3

What investigation can be done to evaluate the widened mediastinum?

Answer 3

Contrasted computed tomography (CT) of the thorax.

A contrasted CT of the thorax was performed (figure 2) and showed a pre-vascular (anterior) mediastinal mass measuring 3.0×7.0×12.0 cm with foci of calcification within, with possible invasion to the left brachiocephalic vein.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Computed tomography of the thorax mediastinal window. a) Axial view and b) coronal view.

The differential diagnosis of pre-vascular mediastinal tumours include thymoma, teratoma/germ cell tumour and lymphoma. In this patient, the anti-striated antibody was positive. Both serum beta-human chorionic gonadotrophin and alpha feto-protein level were normal. The likely diagnosis was a thymoma.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Computed tomography of the thorax mediastinal window (coronal view).

Task 4

Describe the CT scan of the thorax (figure 3).

Answer 4

A CT scan of the thorax mediastinal window (coronal view) revealed a left pre-vascular (anterior) mediastinal mass with poor demarcation with mediastinal great vessels, and mass effect onto the left brachiocephalic vein.

On further questioning, the patient gave a history of video-assisted thoracoscopic surgery performed 12 years ago. Histopathological examination showed a thymic lipoma. On comparison of the CT scans, the thymoma had increased in size. In view of the increase in size of the thymoma and the recurrent symptoms of myasthenia gravis, he was scheduled for a repeat resection of the residual tumour. However, intraoperatively the tumour was inoperable due to its invasiveness involving the pericardium and major vessels, thus surgery was abandoned. Histopathological examination from the biopsy of the tumour showed thymoma AB variant.

He declined chemotherapy and was maintained on a steroid sparing agent, azathioprine 100 mg daily and pyridostigmine 60 mg twice daily. He went on to have three separate episodes of chest infections requiring hospital admissions over a period of 6 months. Sputum culture from one of the admissions grew Pseudomonas aeruginosa and despite treatment he was readmitted with pneumonia within 1 month.

Task 5

What diagnostic investigation would you consider at this point?

Answer 5

Immunoglobulin (Ig) levels.

In view of the history of recurrent episodes of chest infections the Ig levels were checked. The Ig panel showed: IgG 542 mg·dL−1 (normal range 700–1600 mg·dL−1), IgA 26 mg·dL−1 (70–400), and IgM 16.8 mg·dL−1 (40–230). There was an increase in CD8+ T-cells and absence of B-cells with an inverted CD4:CD8 ratio. In this patient, decreased Ig levels suggest a secondary cause of immune deficiency.

Task 6

What is the likely diagnosis?

Answer 6

Good syndrome.

With the evidence of hypogammaglobulinaemia, thymoma and multiple episodes of chest infections, we made a diagnosis of Good syndrome. Good syndrome is a rare disease characterised by adult-onset immunodeficiency with co-existing thymoma and hypogammaglobulinaemia. He was initiated on periodic intravenous Ig (IVIG) to maintain adequate Ig levels. He received a total of 18 cycles of IVIG, with significant reduction of recurrent infections.

Discussion

Good syndrome is a rare association of thymoma and immunodeficiency first described in 1954 by Robert Good [4]. The reported incidence is 0.15 cases per 100 000 population per year in the USA [5]. Patients usually present in the fourth to fifth decade of life either with the diagnosis of thymoma or with severe or chronic infections complications secondary to their immunodeficiency. Pulmonary infection is the most common infectious complication [6]. Bronchiectasis has been reported in up to 45% of patients with Good syndrome [7].

Thymomas are rare slow growing tumours which metastasises to the pleural, pericardium or diaphragm and less commonly to extrathoracic regions [8]. The widely used classification is the four clinical stage Masaoka staging which is based on the extent of local extension. The treatment ranges from complete resection of the thymus in stage 1, combination of chemotherapy neoadjuvant or adjuvant with or without surgery to sequential chemotherapy followed by radiation to individualised therapy in stage IVB [9]. The tumour, node, metastasis staging has also been proposed for evaluating thymoma and thymic carcinoma [10]. It provides information on nodal involvement and dissemination of the tumour which can be clinically useful to direct therapy.

Thymomas can recur even after complete resection has been performed [11]. The diagnosis of thymoma may precede the diagnosis of hypogammaglobulinaemia from as little as 3 months to 18 years and the most common reported histologic type is the AB variant [12].

This syndrome was initially classified as a subset of common variable immunodeficiency [12]. The immunological findings are hypogammaglobulinaemia, few or absent B-cells, an abnormal CD4+:CD8+ T-cell ratio, CD4 T-cell lymphopenia with impaired T-cells mitogenic responses. Patients with Good syndrome usually have reduced serum IgG, IgA and IgM [6]. Good syndrome should be suspected in patients aged >40 years with evidence of antibody deficiency.

The reported mortality for Good syndrome is 46% with the prognosis depending on the severity of associated infectious, haematologic and autoimmune diseases [12]. The prognosis is believed to be worse than other immunodeficiencies [13]. The mainstay of management is thymectomy or debulking of the thymus and Ig replacement [12]. Treatment with Ig maintains a certain level of Ig and prevents infections whilst thymectomy prevents locally invasive growth and metastasis of thymoma.

The aim of IVIG treatment is to bring the IgG trough level >500 mg·dL−1. This has been found to decrease infections and improve lung function in primary immunodeficiency [14]. A recent study by Perez et al. [15] recommended the dosage of IVIG be dependent on a patient's clinical outcome. This suggests that different patients may need higher trough levels to maintain a stable clinical condition.

Good syndrome should be suspected in a patient aged >40 years with thymoma and recurrent infections and unexplained antibody deficiency. It has a significant mortality, therefore, early detection is important. A high index of suspicion and relevant investigations are required to diagnose and treat infections appropriately.

Footnotes

  • Conflict of interest: F.A. Hamid has nothing to disclose.

  • Conflict of interest: A.H.H. Hasbullah has nothing to disclose.

  • Conflict of interest: A. Y-L. Ban has nothing to disclose.

  • Received April 14, 2020.
  • Accepted July 8, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Metlay JP,
    2. Waterer GW,
    3. Long AC, et al.
    Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200: e45–e67. doi:10.1164/rccm.201908-1581ST
    OpenUrlCrossRefPubMed
  2. ↵
    1. Levy ML,
    2. Le Jeune I,
    3. Woodhead MA, et al.
    Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. Prim Care Respir J 2010; 19: 21–27. doi:10.4104/pcrj.2010.00014
    OpenUrlCrossRefPubMed
  3. ↵
    1. Carter BW,
    2. Tomiyama N,
    3. Bhora FY, et al.
    A modern definition of mediastinal compartments. J Thorac Oncol 2014; 9: Suppl. 2, S97–S101. doi:10.1097/JTO.0000000000000292
    OpenUrl
  4. ↵
    1. Kelleher P,
    2. Misbah SA
    . What is Good's syndrome? Immunological abnormalities in patients with thymoma. J Clin Pathol 2003; 56: 12–16. doi:10.1136/jcp.56.1.12
    OpenUrlFREE Full Text
  5. ↵
    1. Malphettes M,
    2. Gérard L,
    3. Galicier L, et al.
    Good syndrome: an adult-onset immunodeficiency remarkable for its high incidence of invasive infections and autoimmune complications. Clin Infect Dis 2015; 61: e13–e19. doi:10.1093/cid/civ269
    OpenUrlCrossRefPubMed
  6. ↵
    1. Tarr PE,
    2. Sneller MC,
    3. Mechanic LJ, et al.
    Infections in patients with immunodeficiency with thymoma (Good syndrome): report of 5 cases and review of the literature. Medicine (Baltimore) 2001; 80: 123–133. doi:10.1097/00005792-200103000-00005
    OpenUrlCrossRefPubMed
  7. ↵
    1. Fox MA,
    2. Lynch DA,
    3. Make BJ
    . Thymoma with hypogammaglobulinemia (Good's syndrome): an unusual cause of bronchiectasis. AJR Am J Roentgenol 1992; 158: 1229–1230. doi:10.2214/ajr.158.6.1590112
    OpenUrlPubMed
  8. ↵
    1. Regnard JF,
    2. Magdeleinat P,
    3. Dromer C, et al.
    Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg 1996; 112: 376–384. doi:10.1016/S0022-5223(96)70265-9
    OpenUrlCrossRefPubMed
  9. ↵
    1. Falkson CB,
    2. Bezjak A,
    3. Darling G, et al.
    The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009; 4: 911–919. doi:10.1097/JTO.0b013e3181a4b8e0
    OpenUrlCrossRefPubMed
  10. ↵
    1. Detterbeck F,
    2. Stratton K,
    3. Giroux D, et al.
    The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014; 9: Suppl. 2, S65–S72. doi:10.1097/JTO.0000000000000290
    OpenUrlCrossRefPubMed
  11. ↵
    1. Awad WI,
    2. Symmans PJ,
    3. Dussek JE
    . Recurrence of stage I thymoma 32 years after total excision. Ann Thorac Surg 1998; 66: 2106–2108. doi:10.1016/S0003-4975(98)01077-7
    OpenUrlCrossRefPubMed
  12. ↵
    1. Kelesidis T,
    2. Yang O
    . Good's syndrome remains a mystery after 55 years: a systematic review of the scientific evidence. Clin Immunol 2010; 135: 347–363. doi:10.1016/j.clim.2010.01.006
    OpenUrlCrossRefPubMed
  13. ↵
    1. Tarr PE,
    2. Sneller MC,
    3. Mechanic LJ, et al.
    Infections in patients with immunodeficiency with thymoma (Good syndrome): report of 5 cases and review of the literature. Medicine (Baltimore) 2001; 80: 123–133. doi:10.1097/00005792-200103000-00005
    OpenUrlCrossRefPubMed
  14. ↵
    1. Roifman CM,
    2. Schroeder H,
    3. Berger M, et al.
    Comparison of the efficacy of IGIV-C, 10%(caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. Int Immunopharmacol 2003; 3: 1325–1333. doi:10.1016/S1567-5769(03)00134-6
    OpenUrlCrossRefPubMed
  15. ↵
    1. Perez EE,
    2. Orange JS,
    3. Bonilla F, et al.
    Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 2017; 139: S1–S46. doi:10.1016/j.jaci.2016.09.023
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Vol 16 Issue 4 Table of Contents
Breathe: 16 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A male with recurrent infections and mediastinal mass
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
A male with recurrent infections and mediastinal mass
Faisal Abdul Hamid, Ahmad Hadyan Husainy Hasbullah, Andrea Yu-Lin Ban
Breathe Dec 2020, 16 (4) 200065; DOI: 10.1183/20734735.0065-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A male with recurrent infections and mediastinal mass
Faisal Abdul Hamid, Ahmad Hadyan Husainy Hasbullah, Andrea Yu-Lin Ban
Breathe Dec 2020, 16 (4) 200065; DOI: 10.1183/20734735.0065-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Expert opinion

  • Bioartificial lungs using de- and recellularisation approaches
  • Fever and dyspnoea in a tracheostomised patient
Show more Expert opinion

Case report

  • Fever and dyspnoea in a tracheostomised patient
  • A double-edged sword
Show more Case report

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2021 by the European Respiratory Society